Iovance Biotherapeutics (IOVA) Provides Regulatory Update for Lifileucel Potency Assays, BLA Submission Now Expected H1 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Iovanace Biotherapeutics (IOVA) Has Strong Cash Cushion Even as CEO Exit Adds to Uncertainties - Mizuho
May 19, 2021 12:42 PM EDTMizuho Securities analyst Mara Goldstein weighed in on Iovanace Biotherapeutics (NASDAQ: IOVA) after the company announced that Maria Fardis, Ph.D. will resign as President and CEO of the company following today's regulatory setback.
"The commercial potential for lifileucel remains but the question... More
Iovanace Biotherapeutics (IOVA) PT Lowered to $33 at Stifel on BLA Push
May 19, 2021 8:05 AM EDTStifel analyst Benjamin Burnett lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $33.00 (from $49.00) while maintaining a Buy rating.
The analyst commented, "Although yesterday's update has us scratching our heads and leaves us with a number of outstanding questions, we remain... More
Iovanace Biotherapeutics (IOVA) PT Lowered to $51 at Chardan Capital Markets on BLA Delay
May 19, 2021 7:58 AM EDTChardan Capital Markets analyst Geulah Livshits lowered the price target on Iovanace Biotherapeutics (NASDAQ: IOVA) to $51.00 (from $54.00) while maintaining a Buy rating.
The analyst commented, "Yesterday, after market close, Iovance Biotherapeutics announced revised guidance for BLA filing on tumor infiltrating lymphocyte (TIL)... More
